EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study

Jun Xiao, Naiqi Zhang, Ziting Gao, Yajing Wei, Hongye Wei, Ziyi Qiu, Kristina Sundquist iD, Jan Sundquist iD, Jianguang Ji, Wuqing Huang iD

European Heart Journal - Cardiovascular Pharmacotherapy · 2025

DOI: 10.1093/ehjcvp/pvae081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Jun Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Fujian Medical University, Union Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Phosphodiesterase 5 Inhibitors, Myocardial Ischemia, Cyclic Nucleotide Phosphodiesterases, Type 5, Myocardial Infarction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accumulating studies reported that several phosphodiesterases (PDEs) inhibitors might have cardiovascular benefits.

Objectives

This study aimed to explore the relationship between genetically-predicted PDEs and ischaemia heart disease via drug target Mendelian randomization (MR) approach, and then examine the effect of inhibitors of identified target on the outcomes by using real-world data. Methods and results In the two-sample MR study, the expression of genes encoding PDEs was used to proxy the level of PDEs and available expression quantitative trait loci (eQTLs) for each target gene were identified as the genetic instruments. The outcomes included coronary heart disease (CHD) and myocardial infarction (MI). In the real-world study, a retrospective cohort was conducted to compare the incidence of outcomes between PDE5 inhibitors and alprostadil use by linking Swedish nationwide registers. MR analyses identified two types of PDEs, PDE5, and PDE8, genetically-predicted expression in blood of the encoded genes was significantly associated with the risk of CHD [odds ratio (OR)PDE5A = 1.22,95% confidence interval (CI) = 1.06–1.40; ORPDE8A = 1.26,95% CI = 1.07–1.49] and MI (ORPDE5A = 1.27,95% CI = 1.09–1.48; ORPDE8A = 1.24,95% CI = 1.04–1.48). Notably, the highest expression of PDE5A was observed in artery aorta, which was also positively related to CHD (OR = 1.17,95% CI = 1.05–1.32) and MI (OR = 1.15,95% CI = 1.02–1.30). Real-world study provided supportive evidence that as compared to alprostadil use, PDE5 inhibitors use significantly reduced the incidence of CHD (adjusted HR = 0.70,95% CI = 0.66–0.73) and MI (adjusted HR = 0.79,95% CI = 0.73–0.84).

Conclusion

This study provided observational and genetic evidence about the protective role of PDE5 inhibition against ischaemic heart disease, indicating the potential of these drugs to be repurposed for ischemia heart disease prevention and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 5 InhibitorsMyocardial IschemiaCyclic Nucleotide Phosphodiesterases, Type 5Myocardial InfarctionPharmacogenomic VariantsHumansMendelian Randomization AnalysisMaleRetrospective StudiesSwedenFemaleMiddle AgedRisk AssessmentAgedQuantitative Trait LociPhenotypeIncidenceGenetic Predisposition to DiseaseRisk FactorsTreatment OutcomeRegistries

Stichwörter der Autor:innen

Drug target Mendelian randomizationEpidemiologyIschaemic heart diseasePhosphodiesterasesReal-world study

Substanzen

Phosphodiesterase 5 InhibitorsCyclic Nucleotide Phosphodiesterases, Type 5PDE5A protein, human

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, Fujian Medical University, Union Hospital, Fuzhou, Fujian, China.
  • Heart Center of Fujian Medical University, Fuzhou, Fujian, China.
  • Center for Primary Health Care Research, Department of Clinical Sciences Malmö, Lund University, Sweden.
  • Nutritional Epidemiology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
  • Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, Fujian, China.
  • Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau, Macao, Macao SAR, China.

ORCID-Profile: Kristina Sundquist, Jan Sundquist, Wuqing Huang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Xiao, J., Zhang, N., Gao, Z., Wei, Y., Wei, H., Qiu, Z., Sundquist, K., Sundquist, J., Ji, J., & Huang, W. (2025). Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae081

Vancouver

Xiao J, Zhang N, Gao Z, Wei Y, Wei H, Qiu Z, et al. Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae081

BibTeX
@article{Xiao2025,
  author = {Xiao, Jun and Zhang, Naiqi and Gao, Ziting and Wei, Yajing and Wei, Hongye and Qiu, Ziyi and Sundquist, Kristina and Sundquist, Jan and Ji, Jianguang and Huang, Wuqing},
  title = {Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2025},
  doi = {10.1093/ehjcvp/pvae081}
}
Kostenlos starten →